Previous product
Back to products
Rydapt (midostaurin)
CHF17,528.19
Next product
Tepezza (teprotumumab-trbw)
CHF23,181.07
Tagrisso (osimertinib)
CHF6,838.00
Tagrisso (osimertinib) is a medicine for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with a T790M mutation in the epidermal growth factor receptor (EGFR) gene.
Reviews
There are no reviews yet.